MetaVia Inc. (NASDAQ: MTVA) received Institutional Review Board approval to begin Phase 1 Part 3 clinical trials of DA-1726, its ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE